Raw data supporting Jaaks and Coker et al., 2022 (DOI: 10.1038/s41586-022-04437-2). Drug combination data for all tissues, from original screen. Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.

Raw data supporting Jaaks and Coker et al., 2022 (DOI: 10.1038/s41586-022-04437-2). Drug combination data for all tissues, from validation screen.
Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.

Raw data supporting Jaaks and Coker et al., 2022 (DOI: 10.1038/s41586-022-04437-2). Glossary of metrics in the raw data files for the anchored drug combination screens.
Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.

Raw data supporting Jaaks and Coker et al., 2022 (DOI: 10.1038/s41586-022-04437-2). Glossary of metrics in the raw data files for the anchored drug combination screens.
Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.

Raw data supporting Jaaks and Coker et al., 2022 (DOI: 10.1038/s41586-022-04437-2). Drug combination data for all tissues, from validation screen.
Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.

Raw data supporting Jaaks and Coker et al., 2022 (DOI: 10.1038/s41586-022-04437-2). Drug combination data for all tissues, from original screen. Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.

Raw data supporting Jaaks and Coker et al., 2022 (10.1038/s41586-022-04437-2). Raw data from initial drug combination screen using cancer cell lines. Cell line viability assay measured by fluorescence intensity.
Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.

Raw data supporting Jaaks and Coker et al., 2022 (10.1038/s41586-022-04437-2). Raw data from initial drug combination screen using cancer cell lines. Cell line viability assay measured by fluorescence intensity.
Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.

Raw data supporting Jaaks and Coker et al., 2022 (10.1038/s41586-022-04437-2). Raw data from day 1 plates matched to the initial drug combination screen using cancer cell lines. Cell line viability assay measured by fluorescence intensity.
Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.

Raw data supporting Jaaks and Coker et al., 2022 (10.1038/s41586-022-04437-2). Raw data from day 1 plates matched to the initial drug combination screen using cancer cell lines. Cell line viability assay measured by fluorescence intensity.
Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.